Literature DB >> 23416052

Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor.

Javier G Ogembo1, Lakshmi Kannan, Ionita Ghiran, Anne Nicholson-Weller, Robert W Finberg, George C Tsokos, Joyce D Fingeroth.   

Abstract

Epstein-Barr virus (EBV) attachment to primary B cells initiates virus entry. Although CD21 is the only known receptor for EBVgp350/220, a recent report documents EBV-infected B cells from a patient genetically deficient in CD21. On normal resting B cells, CD21 forms two membrane complexes: one with CD19 and another with CD35. Whereas the CD21/CD19 complex is widely retained on immortalized and B cell tumor lines, the related complement-regulatory protein CD35 is lost. To determine the role(s) of CD35 in initial infection, we transduced a CD21-negative pre-B cell and myeloid leukemia line with CD35, CD21, or both. Cells expressing CD35 alone bound gp350/220 and became latently infected when the fusion receptor HLA II was coexpressed. Temporal, biophysical, and structural characteristics of CD35-mediated infection were distinct from CD21. Identification of CD35 as an EBV receptor uncovers a salient role in primary infection, addresses unsettled questions of virus tropism, and underscores the importance of EBVgp350/220 for vaccine development.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23416052      PMCID: PMC3633082          DOI: 10.1016/j.celrep.2013.01.023

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  58 in total

1.  Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2).

Authors:  G R Nemerow; R Wolfert; M E McNaughton; N R Cooper
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

2.  Progenitor and pre-B lymphocytes transformed by Epstein-Barr virus.

Authors:  I Ernberg; K Falk; M Hansson
Journal:  Int J Cancer       Date:  1987-02-15       Impact factor: 7.396

3.  Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.

Authors:  J D Fingeroth; J J Weis; T F Tedder; J L Strominger; P A Biro; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

4.  Genetic CD21 deficiency is associated with hypogammaglobulinemia.

Authors:  Jens Thiel; Lucas Kimmig; Ulrich Salzer; Magdalena Grudzien; Dirk Lebrecht; Tina Hagena; Ruth Draeger; Nadine Voelxen; Nadine Völxen; Astrid Bergbreiter; Stephanie Jennings; Sylvia Gutenberger; Annette Aichem; Harald Illges; Jonathan P Hannan; Anne-Kathrin Kienzler; Marta Rizzi; Hermann Eibel; Hans-Hartmut Peter; Klaus Warnatz; Bodo Grimbacher; Jörg-Andres Rump; Michael Schlesier
Journal:  J Allergy Clin Immunol       Date:  2011-10-27       Impact factor: 10.793

5.  EBV infection of mitogen-stimulated human B lymphocytes.

Authors:  L Einhorn; E Klein
Journal:  Int J Cancer       Date:  1981-02-15       Impact factor: 7.396

6.  Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process.

Authors:  G R Nemerow; N R Cooper
Journal:  Virology       Date:  1984-01-15       Impact factor: 3.616

7.  Frequency of B-lymphocyte transformation by Epstein-Barr virus decreases with entry into the cell cycle.

Authors:  A J Roome; C L Reading
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

8.  gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor.

Authors:  R Frade; M Barel; B Ehlin-Henriksson; G Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

9.  Monoclonal antibodies to the human C3b/C4b receptor (CR1) enhance specific B cell differentiation.

Authors:  L Weiss; J F Delfraissy; A Vazquez; C Wallon; P Galanaud; M D Kazatchkine
Journal:  J Immunol       Date:  1987-05-01       Impact factor: 5.422

Review 10.  Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes.

Authors:  Salomé LeibundGut-Landmann; Jean-Marc Waldburger; Michal Krawczyk; Luc A Otten; Tobias Suter; Adriano Fontana; Hans Acha-Orbea; Walter Reith
Journal:  Eur J Immunol       Date:  2004-06       Impact factor: 5.532

View more
  49 in total

1.  Glycoprotein K8.1A of Kaposi's Sarcoma-Associated Herpesvirus Is a Critical B Cell Tropism Determinant Independent of Its Heparan Sulfate Binding Activity.

Authors:  Stephen J Dollery; Rey J Santiago-Crespo; Deboeeta Chatterjee; Edward A Berger
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

2.  High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.

Authors:  Eric R Weiss; Galit Alter; Javier Gordon Ogembo; Jennifer L Henderson; Barbara Tabak; Yasin Bakiş; Mohan Somasundaran; Manuel Garber; Liisa Selin; Katherine Luzuriaga
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

3.  Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells.

Authors:  Dan Xiong; Yong Du; Hong-Bo Wang; Bo Zhao; Hua Zhang; Yan Li; Li-Juan Hu; Jing-Yan Cao; Qian Zhong; Wan-Li Liu; Man-Zhi Li; Xiao-Feng Zhu; Sai Wah Tsao; Lindsey M Hutt-Fletcher; Erwei Song; Yi-Xin Zeng; Elliott Kieff; Mu-Sheng Zeng
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-19       Impact factor: 11.205

Review 4.  Extracellular Vesicles Exploit Viral Entry Routes for Cargo Delivery.

Authors:  Helena M van Dongen; Niala Masoumi; Kenneth W Witwer; D Michiel Pegtel
Journal:  Microbiol Mol Biol Rev       Date:  2016-03-02       Impact factor: 11.056

5.  Analysis of host gene expression changes reveals distinct roles for the cytoplasmic domain of the Epstein-Barr virus receptor/CD21 in B-cell maturation, activation, and initiation of virus infection.

Authors:  Mohamed S Arredouani; Manoj K Bhasin; David R Sage; Laura K Dunn; Michael B Gill; Deep Agnani; Towia A Libermann; Joyce D Fingeroth
Journal:  J Virol       Date:  2014-03-05       Impact factor: 5.103

6.  An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus.

Authors:  Joost Snijder; Michael S Ortego; Connor Weidle; Andrew B Stuart; Matthew D Gray; M Juliana McElrath; Marie Pancera; David Veesler; Andrew T McGuire
Journal:  Immunity       Date:  2018-04-17       Impact factor: 31.745

7.  Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies.

Authors:  Karthik Sathiyamoorthy; Jiansen Jiang; Britta S Möhl; Jia Chen; Z Hong Zhou; Richard Longnecker; Theodore S Jardetzky
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-22       Impact factor: 11.205

8.  gp96 Is Critical for both Human Herpesvirus 6A (HHV-6A) and HHV-6B Infections.

Authors:  Jingjing Ma; Junli Jia; Xuefeng Jiang; Mengyuan Xu; Jinfeng Guo; Tian Tang; Xianyi Xu; Zhisheng Wu; Benshun Hu; Kun Yao; Lingyun Li; Huamin Tang
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

Review 9.  Viral Carcinogenesis Beyond Malignant Transformation: EBV in the Progression of Human Cancers.

Authors:  Deilson Elgui de Oliveira; Bárbara G Müller-Coan; Joseph S Pagano
Journal:  Trends Microbiol       Date:  2016-04-07       Impact factor: 17.079

10.  The BDLF3 gene product of Epstein-Barr virus, gp150, mediates non-productive binding to heparan sulfate on epithelial cells and only the binding domain of CD21 is required for infection.

Authors:  Liudmila S Chesnokova; Sarah M Valencia; Lindsey M Hutt-Fletcher
Journal:  Virology       Date:  2016-04-08       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.